Summary Platelet sensitivity to prostacyclin (PG12) was determined in normal male and female subjects, and in patients with benign and malignant tumours of the breast.
the menstrual cycle; post-menopausal women gave similar values to normal males and to pre-menopausal women in the 1st phase of the cycle.
No significant differences were found between normal subjects and patients with benign or malignant tumours of the breast when account was taken of the status of the patient in relation to the phase of the menstrual cycle and the menopause.
The importance of the hormonal status in evaluating changes in platelet sensitivity in patients with breast cancer is strongly emphasised.
Prostacyclin (PGl2) may play an important role in the control of vascular and platelet homeostasis (Bunting et al., 1983) . Based upon the assumption that platelet-tumour cell and/or platelet-tumour cell-vessel wall interactions can influence the metastasis of tumour cells, Honn and coworkers (Honn, 1982; Honn et al., 1983) suggested that the presence of malignant tumours could disrupt the intravascular balance between PG12 and thromboxane A2 (TXA2), the main endogenous antagonist of PG12 (Bunting et al., 1983) , in favour of platelet aggregation, thus favouring the likelihood of metastasis.
Another factor that may contribute to changes in platelet aggregation in patients with tumours is the sensitivity of the platelets to PGl2. This aspect may be investigated in vitro using synthetic PGI2, and probably is an essential part of the biological activity of PG12 through its binding to platelet membranes, and in the regulation of haemostatic balance (Schillinger & Prior, 1980) .
Since studies on humans have demonstrated that patients with colonic cancer have a decreased platelet sensitivity to PG12 (Gisinger et al., 1982) and malignant tumours of the breast produce substantial amounts of PG12 (Bennett et al., 1983) we decided to investigate the platelet sensitivity to PG12 in patients with benign and malignant tumours of the breast.
Subjects and methods

Subjects
Four groups of subjects have been studied: 1) 26 healthy normal female subjects; 2) 14 patients with benign tumours of the breast; 3) 30 patients with malignant tumours of the breast; 4) 16 men as healthy controls.
The range and mean values + s.d. of ages of all subjects and the number of women in pre-and post-menopause are given in Table I . None of the subjects was on oral contraceptives and 7 healthy women in pre-menopause were studied both in the first and second phase of the same cycle. In 4 normal subjects the estimations were repeated during different menstrual cycles. Eight men, 1 woman with a malignant tumour and I with a benign tumour of the breast smoked more than 10 cigarettes a day; none of the subjects had taken drugs known to affect prostaglandin metabolism in the two weeks before the blood sampling, or had diabetes mellitus or coronary heart diseases. In the group with malignant tumours 3 patients had hypertension, 3 were obese. 
Results
The mean values + s.e. of the IC50 for prostacyclin on the ADP-induced platelet aggregation assay are shown in Table II for the 4 groups of subjects studied: where appropriate, the groups are subdivided so as to separate values found during the first or second phases of the menstrual cycle, and after the menopause. It can be seen by inspection of column "a" of Table II that there is no significant difference between the mean values for all subjects studied in Group 1 (normal females) and Group 4 (normal males). Moreover, there is no significant difference in the overall mean values for patients with tumours of the breast (Table II , column "a"; Groups 2 and 3) and normal female subjects (Group 1).
In contrast to the lack of significant differences between the overall mean values just mentioned, when the female Groups 1-3 are separated into first or second phases of the menstrual cycle and postmenopausal sub-groups (Table II, columns "b", "c", "e") then significant differences become evident. There is a considerable increase in the IC50 values for healthy women in the second phase of the cycle compared to the first phase; the postmenopausal sub-group (column "e") for normal women gives a mean value that is very similar to that obtained in the first phase of the cycle in premenopausal subjects. The stage of the cycle in the subjects studied was calculated on the basis of the time from the onset of menstruation, and, in some normal subjects, was checked by measurements of body temperature and progesterone levels in the plasma. Where the progesterone concentration indicated a failure of ovulation the value for the second phase of the cycle was deleted (3 subjects). In fact where progesterone had not increased in the presumed second phase of the cycle, the IC50 value was in the range typical of first phase samples. The latter result suggests that the change in IC50 that is observed between the first and second phases of the cycle is probably a more or less direct consequence of hormonal influences.
The mean value for normal males (Group 4, column "a") corresponds to that found for normal pre-menopausal women in the first phase of the cycle, and for post-menopausal women.
Although the overall difference between the mean values obtained for first and second phases of the menstrual cycle is not so large in patients with tumours of the breast (Groups 2 and 3) as in normal subjects (Group 1), the same phenomenon is observed: a higher value for IC50 in the second phase compared to the first phase of the cycle. This difference is statistically significant for the benign tumour group, but is not statistically significant in the malignant tumour group due to a larger variability between patients in Group 3 than Groups 1 and 2. The variation between individual values is clearly shown in the "scatter diagram" (Figure 1) , which emphasises the clear differences found between first and second phases of the menstrual cycle in relation to the IC50 values for PG12.
The IC50 values for the malignant tumour group (Group 3) were also considered in relation to the existence of hypertension or obesity, and to the occurrence of lymph node metastases. Although the number of patients with hypertension was small, and all were post-menopausal, there was a tendency for the IC50 values to be increased. No apparent change in the IC50 occurred in association with obesity. In patients with lymph node metastases, both before or after the menopause, there was no significant change in the IC50 values compared to corresponding patients without metastases.
Discussion
It is clear from the results presented in Table II (Sinzinger et al., 1981 (Sinkovics, 1979) . The rather smaller difference observed between the first and second phases of the menstrual cycle in the benign tumour group compared to normal (0.86-1.21 compared to 0.81-1.37) may be possibly a reflection of the higher average age in Group 2 (39 + 6 years) compared to Group 1 (28+4 years).
The results found for healthy women and for women with malignant breast tumours (Table II) are similar to our preliminary findings (Benedetto et al., 1984) with an important proviso that is detailed below. In that preliminary report we concluded from our results obtained on 9 control and 9 malignant samples that the IC50 values for the malignant tumour group were smaller than those found in the control samples. However, by chance, our early control samples were mostly from women in the 2nd phase of the cycle (equivalent to Group lc, Table II), and our early malignant samples were mostly from post-menopausal women (equivalent to Group 3e, Table II ). In consequence, our preliminary report compared women of dissimilar hormonal status; our present results are indeed very similar for those two groups of samples (Group lc vs. Group 3e). However, when women of comparable hormonal status are considered, which is a major point emphasised here, and uncovered as a result of this much larger study, there are no significant differences between the normal and tumour groups. These results show that platelets prepared from the blood of patients with malignant tumours of the breast are not significantly different in their response to PG12 in relation to ADPinduced aggregation. If platelets of cancer patients show enhanced aggregation in vivo, as predicted by Honn's hypothesis (Honn 1982; Honn et al., 1983 ) then other contributory factors should be investigated, such as local concentrations of PG!2 and TXA2, and sensitivity of platelets to TXA2.
Finally, we wish to emphasise the importance, in studies of this kind on PG12 sensitivity, of clearly separating the sub-groups of patients and normal subjects with different hormonal status; unless this is controlled then important differences between groups under evaluation may be overlooked.
